- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01772550
Study of Effectiveness of Smaller Gauge Fenestrated Catheters for Use in IV Contrast Enhanced CT Scans (ARCTR05)
A Randomized Controlled Study to Determine Whether Smaller Gauge Fenestrated Catheters Are as Effective as Larger Gauge Non-fenestrated Catheters for Use in IV Contrast Enhanced CT Scans
The purpose of this study is to compare multidetector computed tomography (CT) image quality following peripheral venous high pressure injection of iodinated intravenous contrast media between a 20 gauge (GA) fenestrated, intravenous catheter (BD Nexiva™ Diffusics™) and an 18 GA non-fenestrated, intravenous catheter.
In the contrast enhanced CT procedure (CECT), a machine (power injector) is used to rapidly deliver contrast agent to an individual's circulatory system. The contrast allows for greater differentiation of tissues in images of the area of interest, affording a better opportunity to visually assess the area and hence make a more accurate diagnosis.
CECT often requires a high rate of contrast flow (≥ 5 mL/sec) through the IV catheter to provide sufficient contrast for an acceptable image. Typically an 18 GA IV catheter is required to achieve these high flow rates; however, often the patient does not have a vein that will accommodate this large size catheter. The BD Nexiva™ Diffusics™ IV catheter is designed to deliver a higher flow rate than a conventional catheter of the same gauge by incorporating fenestrations (small openings) near the tip of the catheter that allow fluid to exit the catheter in addition to that which normally exits through the main opening at the tip of the catheter.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective study performed in adult human subjects who have been referred for a CECT. The study will occur during a single visit. Once consented and enrolled, subjects whose antecubital veins can accommodate an 18 GA IV catheter (as assessed by the Inserter or designee of the PI), will be randomized to receive either a conventional 18 GA IV catheter (reference, control) or a 20 GA BD Nexiva™ Diffusics™ IV catheter (test). Subjects whose veins are not considered suitable for an 18 GA IV catheter will be placed in a non-randomized cohort for placement of a 20 GA BD Nexiva™ Diffusics™ IV catheter. Subjects will receive one (1) catheter for the study.
The primary objective of this study is to compare multidetector computed tomography (CT) image quality following peripheral venous high pressure injection of iodinated intravenous contrast media between a 20 GA fenestrated, intravenous catheter (BD Nexiva™ Diffusics™) and an 18 GA non-fenestrated, intravenous catheter. The 20 GA BD Nexiva™ Diffusics™ IV catheter will be considered non-inferior to conventional 18 GA IV catheters if the 95% upper bound for the difference in percentage of images of acceptable quality between the images acquired using the 18 GA IV catheters and the 20 GA BD Nexiva™ Diffusics™ IV catheters is less than 15%.
Study catheters will be inserted by appropriately licensed healthcare professionals (Inserters). Prior to enrollment, potential Inserters will be trained and qualified by the Sponsor on proper use of the BD Nexiva™ Diffusics™ IV catheter in both an artificial hand model and then in human patients. Inserters will then be expected to use the test product for a period of two (2) weeks, in order to gain familiarity with the product. Because BD Nexiva™ Diffusics™ IV catheters are not currently used in the Johns Hopkins Outpatient Center, the Sponsor will provide BD Nexiva™ Diffusics™ IV catheters for use during this training and familiarization period.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Outpatient Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be at least 18 years old at the time of enrollment,
- Must meet the investigational site's standard criteria for multi-detector Computed Tomography (CT),
- Per institutional protocol, the ordered scan must require a flow rate of 5.0-7.0 mL/sec (inclusive) for Visipaque 320 or 5.0-7.5 mL/sec (inclusive) for Omnipaque350 warmed to 35°C,
- The planned catheter insertion site must be located in the antecubital area,
- Must require any of the following multi-detector CT procedures: CT angiogram,CT pancreas,CT liver, CT kidney, Cardiac CT,
- Must be willing and able to provide informed consent,
- Must be able to read, write, and follow instructions in English,
- Must be able to accommodate a 20 G x 1.00 inch IV catheter,
Exclusion Criteria:
- Preexisting IV catheter or contrast-compatible port in place suitable for power injection with the intent to be used for contrast enhanced CT,
- Subjects who have reported an adverse reaction that precludes use of iodine-based contrast media,
- Subjects who have had a prior extravasation event involving solutions considered irritants or vesicants.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 20 Gauge BD Nexiva Diffusics
During their routinely scheduled contrast-enhanced computed tomography procedure, subjects in this arm will receive IV contrast media injected via the fenestrated 20GA BD Nexiva Diffusics single port IV catheter (20GA x 1.00 inch).
|
The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm. If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies.
Other Names:
|
Active Comparator: 18 Gauge Conventional Catheter
During their routinely scheduled contrast-enhanced computed tomography procedure, subjects in this arm will receive IV contrast media injected via the non-fenestrated 18GA Conventional Catheter (18 GA x 1.25 inch Smiths Medical Jelco® IV Catheter).
|
The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm. If after the first attempt, there is no vein in the contralateral arm that can accommodate an 18 gauge catheter, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies.
Other Names:
|
Experimental: BD Nexiva Diffusics - Nonrandomized
Subjects whose veins were not suitable for an 18 GA IV Catheter were assigned to this non-randomized arm.
During their routinely scheduled CECT procedure, subjects receive IV contrast medium injected via the fenestrated 20GA BD Nexiva Diffusics single port IV catheter (20GA x 1.00 inch)
|
The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm. If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptable Image Quality
Time Frame: at the time of image assessment
|
Study images were assessed by a US board-certified radiologist to determine whether the image is of acceptable quality. The radiologist was not informed of the study device used for the injection that produced the image under evaluation. Subjective image quality assessment for acceptability was determined by:
In the case of a non-concurrence, the Principal Investigator assessed the image and his or her assessment had final authority. |
at the time of image assessment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Abdomen CT - Average Hounsfield Units as a Measure of Aortic Contrast Delivery and Enhancement in Randomized Subjects
Time Frame: at the time of image assessment
|
Objective image quality assessment was performed by a board-certified Research Radiologist, by measuring the post-contrast aortic attenuation in Hounsfield Units (HU) at either the aortic arch if chest is imaged or the diaphragmatic crus and above the aortic bifurcation or on the most inferior image on the arterial phase.
Hounsfield units within the proximal and distal aorta were recorded for each subject image reviewed.
The average number of HU for each group in the Study are reported descriptively; formal acceptance criteria for this objective are not specified.
|
at the time of image assessment
|
Chest CT - Average Hounsfield Units as a Measure of Aortic Contrast Delivery and Enhancement in Subjects Whose Veins Could Accommodate an 18 GA IV Catheter (Randomized Subjects)
Time Frame: at the time of image assessment
|
Objective image quality assessment was performed by a board-certified Research Radiologist, by measuring the post-contrast aortic attenuation in Hounsfield Units (HU) at either the aortic arch if chest is imaged or the diaphragmatic crus and above the aortic bifurcation or on the most inferior image on the arterial phase.
Hounsfield units within the proximal and distal aorta were recorded for each subject image reviewed.
The average number of HU for each group in the Study are reported descriptively; formal acceptance criteria for this objective are not specified.
|
at the time of image assessment
|
Complete Chest and Abdomen CT - Average Hounsfield Units as a Measure of Aortic Contrast Delivery and Enhancement in Subjects Whose Veins Could Accommodate an 18 GA IV Catheter (Randomized Subjects)
Time Frame: at the time of image assessment
|
Objective image quality assessment was performed by a board-certified Research Radiologist, by measuring the post-contrast aortic attenuation in Hounsfield Units (HU) at either the aortic arch if chest is imaged or the diaphragmatic crus and above the aortic bifurcation or on the most inferior image on the arterial phase.
Hounsfield units within the proximal and distal aorta were recorded for each subject image reviewed.
The average number of HU for each group in the Study are reported descriptively; formal acceptance criteria for this objective are not specified.
|
at the time of image assessment
|
Maximum Flow Rate
Time Frame: immediately after power injection
|
Maximum flow rate guidelines provided in the BD Nexiva Diffusics Instructions for Use were to be followed.
The maximum flow rate (milliliters per second, or mL/sec) utilized was recorded by the Radiology Technician immediately following the power injection of iodinated intravenous contrast media.
Results are descriptively summarized; no formal acceptance criteria were specified by the protocol.
|
immediately after power injection
|
Catheter Insertion Success
Time Frame: immediately after catheter insertion
|
Insertion is successful when the catheter can be flushed or infused to demonstrate patency, and there is no inadvertent administration of a solution or medication into the tissue surrounding the IV catheter. The number of participants with successfully inserted catheters after the first or second insertion attempt is reported. The clinician inserting the IV catheter made a clinical judgement as to whether the catheter was successfully placed; the protocol did not define more specific criteria. Catheter insertion success rates were determined from each IV insertion attempted in the Study. |
immediately after catheter insertion
|
Extravasation of Contrast Media
Time Frame: upon contrast injection
|
The number of subjects who experienced injections with extravasation of contrast media is reported.
|
upon contrast injection
|
Automatic Injection Shutoff
Time Frame: immediately after contrast injection
|
The number of subjects who experienced injections with automatic injection shutoff is reported.
Immediately after the power injection, the injection technician recorded whether or not an automatic injection shutoff occurred.
|
immediately after contrast injection
|
High Pressure Alarm
Time Frame: immediately after contrast injection
|
The number of subjects who experienced injections with activation of the high pressure alarm is reported.
Immediately following the power injection, the clinician performing the power injection recorded whether or not the high pressure alarm sounded.
|
immediately after contrast injection
|
Catheter Dislodgement
Time Frame: Immediately following power injection
|
The number of subjects who experienced partial or complete dislodgement of the catheter from the subject prior to power injection procedure completion is reported.
The information about the IV catheter was collected by a clinically qualified study staff member (e.g., the Principal or sub-Investigator, or Study Coordinator) after the power injection.
|
Immediately following power injection
|
Catheter Transfixation
Time Frame: immediately after power injection
|
The number of subjects who experienced catheter transfixation (the IV penetrating the opposite wall of the vein) is reported.
This information was collected by a clinically qualified study staff member (e.g., the Principal or sub-Investigator, or Study Coordinator) after the power injection.
|
immediately after power injection
|
Catheter Integrity Failure
Time Frame: immediately after power injection
|
Catheter integrity failure generally refers to any portion of the device breaking or malfunctioning so that its proper function is no longer assured. In this study, the most relevant catheter integrity failures to be assessed were fluid leakage, tubing rupture, or tubing separation from the hub. The number of subjects who experienced injections with a catheter integrity failure during injection is reported. The information about the IV catheter was collected by a clinically qualified study staff member (e.g., the Principal or sub-Investigator, or Study Coordinator) after the power injection. |
immediately after power injection
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Elliot Fishman, MD, Johns Hopkins University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- INF-11-ARCTR05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contrast Enhanced Computed Tomography
-
The University of Texas Health Science Center,...CompletedContrast Enhanced Computed Tomography (CT) ScanningUnited States
-
Bracco Diagnostics, IncCompletedPatients Undergoing Contrast Enhanced Multidetector Computed Tomography of the Chest, Abdomen, Liver or Aorta for Any Diagnostic CauseUnited States, Italy
-
BayerCompletedComputed TomographyAustralia, Netherlands
-
University Health Network, TorontoCompletedComputed Tomography | Image Quality
-
Cairo UniversityUnknownCone Beam Computed TomographyEgypt
-
BayerCompletedDiagnostic Imaging | Computed TomographyUnited States, Colombia, Korea, Republic of, India
-
Seoul National University HospitalUnknownComputed Tomography | Double Lumen TubeKorea, Republic of
-
Cairo UniversityUnknownCone-Beam Computed TomographyEgypt
-
Abramson Cancer Center at Penn MedicineVarian Medical SystemsRecruiting
-
Cairo UniversityRecruiting
Clinical Trials on 20GA BD Nexiva Diffusics
-
University of Texas Southwestern Medical CenterBecton, Dickinson and CompanyCompleted
-
The University of Texas Health Science Center,...CompletedContrast Enhanced Computed Tomography (CT) ScanningUnited States
-
Gülçin Özalp GerçekerCompletedCatheter Complications | Catheter LeakageTurkey
-
Hospital San Carlos, MadridFoundation for Biomedical Research and InnovationCompletedCatheterization, PeripheralSpain